Catalyst Dossier · compiled by CeliA 🧫
Cellectar Biosciences, Inc. (CLRB)
Pharmaceutical Preparations · market cap $22M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-06-30 (est.)
Phase 3
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Cellectar Biosciences (CLRB) is a micro-cap clinical-stage pharmaceutical company with an 11-person staff and a $20M market cap, running a multi-asset pipeline that includes a Phase 3 paclitaxel program in Non-Small Cell Lung Cancer and a Phase 2 iopofosine I-131 program in Waldenström Macroglobulinemia. The company carries only $8.3M in cash against a runway of roughly five months, making near-term financing a near-certainty.
The catalyst path
- 2027-06-30 (est.)Phase 3imp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NOV-205 | Phase 2 | Hepatitis C |
| Iopofosine I 131 single dose | Phase 2 | Waldenstrom Macroglobulinemia |
| NOV-002 | Phase 3 | Ovarian Cancer |
Price & technical context
3-month
-11.0%
6-month
-22.2%
12-month
-41.4%
52-wk range
$2.23–$6.17
vs 50-day MA
+1.4%
vs 200-day MA
-13.5%
Realized vol
80.3%
Max drawdown
-97.5%
Daily closes through 2026-08-12. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CLRB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.